📊 HRMY Key Takeaways
Is HRMY a Good Investment? Thesis Analysis
Harmony Biosciences demonstrates exceptional financial health with a fortress balance sheet, 77.2% gross margins, and 40.1% free cash flow margins in a capital-light business model. However, flat net income growth (+0% YoY) despite 21.5% revenue growth warrants investigation into margin compression and operational efficiency, presenting both opportunity and execution risk.
Why Buy HRMY? Key Strengths
- Exceptional gross margin of 77.2% with 24.0% operating margin indicates strong pricing power and operational efficiency in pharmaceuticals
- Fortress balance sheet with $752.5M cash, low 0.19x debt-to-equity ratio, and 3.60x current ratio provides significant strategic flexibility
- Outstanding free cash flow generation of $347.9M (40.1% FCF margin) from capital-light operations with minimal $310K capex requirement
- Strong return metrics with 18.2% ROE and 12.5% ROA demonstrate excellent capital deployment and shareholder value creation
HRMY Investment Risks to Consider
- Net income growth flat at 0% YoY despite 21.5% revenue growth suggests margin pressure or operating expense deleverage requiring investigation
- Pharmaceutical sector inherent risks including regulatory changes, patent cliffs, drug competition, and clinical trial uncertainties
- Elevated insider activity with 10 Form 4 filings in 90 days requires monitoring for potential concerns or shifts in management sentiment
Key Metrics to Watch
- Net income growth reacceleration and driver analysis of YoY margin compression
- Gross margin preservation as revenue scales and gross profit sustainability
- Operating expense ratio trends and ability to leverage fixed cost base
- Free cash flow sustainability and working capital efficiency quarter-over-quarter
HRMY Financial Metrics
💡 AI Analyst Insight
The 40.1% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.60x current ratio provides a solid financial cushion.
HRMY Profitability Ratios
HRMY vs Healthcare Sector
How Harmony Biosciences Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HRMY Overvalued or Undervalued?
Based on fundamental analysis, Harmony Biosciences Holdings, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HRMY Balance Sheet & Liquidity
HRMY 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Harmony Biosciences Holdings, Inc.'s revenue has grown significantly by 184% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.13 reflects profitable operations.
HRMY Growth Metrics (YoY)
HRMY Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $186.0M | $46.1M | $0.79 |
| Q2 2025 | $172.8M | $11.6M | $0.20 |
| Q1 2025 | $154.6M | $38.3M | $0.67 |
| Q3 2024 | $160.3M | $38.5M | $0.63 |
| Q2 2024 | $134.2M | $11.6M | $0.20 |
| Q1 2024 | $119.1M | $29.5M | $0.48 |
| Q3 2023 | $117.2M | $38.5M | $0.63 |
| Q2 2023 | $107.0M | $23.5M | $0.39 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HRMY Capital Allocation
HRMY SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Harmony Biosciences Holdings, Inc. (CIK: 0001802665)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HRMY
What is the AI rating for HRMY?
Harmony Biosciences Holdings, Inc. (HRMY) has an AI rating of BUY with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are HRMY's key strengths?
Claude: Exceptional gross margin of 77.2% with 24.0% operating margin indicates strong pricing power and operational efficiency in pharmaceuticals. Fortress balance sheet with $752.5M cash, low 0.19x debt-to-equity ratio, and 3.60x current ratio provides significant strategic flexibility.
What are the risks of investing in HRMY?
Claude: Net income growth flat at 0% YoY despite 21.5% revenue growth suggests margin pressure or operating expense deleverage requiring investigation. Pharmaceutical sector inherent risks including regulatory changes, patent cliffs, drug competition, and clinical trial uncertainties.
What is HRMY's revenue and growth?
Harmony Biosciences Holdings, Inc. reported revenue of $868.5M.
Does HRMY pay dividends?
Harmony Biosciences Holdings, Inc. does not currently pay dividends.
Where can I find HRMY SEC filings?
Official SEC filings for Harmony Biosciences Holdings, Inc. (CIK: 0001802665) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HRMY's EPS?
Harmony Biosciences Holdings, Inc. has a diluted EPS of $2.71.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HRMY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Harmony Biosciences Holdings, Inc. has a BUY rating with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is HRMY stock overvalued or undervalued?
Valuation metrics for HRMY: ROE of 18.2% (sector avg: 15%), net margin of 18.3% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy HRMY stock in 2026?
Our dual AI analysis gives Harmony Biosciences Holdings, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is HRMY's free cash flow?
Harmony Biosciences Holdings, Inc.'s operating cash flow is $348.2M, with capital expenditures of $310.0K. FCF margin is 40.1%.
How does HRMY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 18.3% (avg: 12%), ROE 18.2% (avg: 15%), current ratio 3.60 (avg: 2).